

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
Details : 5-MeO-DMT is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 06, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Hospital Descentralizado Dr. Marcial V. Quiroga | Universidad Católica de Cuyo
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering
GH Research Announces Pricing of $150 Million Public Offering
Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 04, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering
GH Research Announces Proposed Public Offering
Details : The procceds will used to fund the clinical development of company's lead product GH001 (mebufotenin), which is being evaluated in patients with bipolar II disorder & other Psychiatry disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 03, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Cantor Fitzgerald
Deal Size : $150.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research’s GH001 Meets Primary Endpoint in Phase 2b TRD Trial (-15.5 MADRS)
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 03, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of treatment-resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 31, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
GH Research Meets Primary Endpoint in Phase 2a Trials of GH001
Details : GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. It is being evaluated for the treatment of postpartum depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
Details : 5-Methoxy-N,N-Dimethyltryptamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomind Reports Positive Phase 2 Results of BMND08 for Depression in Alzheimer’s Disease
Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Mebufotenin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 29, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMND08 is a proprietary sublingual formulation of 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT"), being investigated as a potential treatment of anxiety and depression in alzheimer’s disease.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
